Acetamide

Acetamide

SCHEMBL16335345

CC(N)=O.Nc1ccc(Cl)cc1C(=O)c1ccccc1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.59
MAPT P10636 5/20 0.57
POLB P06746 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
GFER P55789 1/20 0.56
KMT2A Q03164 1/20 0.56
GAA P10253 1/20 0.56
S100B P04271 1/20 0.55
NOS2 P35228 1/20 0.54
GABRP O00591 1/20 0.53
GABRD O14764 1/20 0.53
GABRA1 P14867 1/20 0.53
GABRB1 P18505 1/20 0.53
GABRG2 P18507 1/20 0.53
GABRB3 P28472 1/20 0.53
GABRA5 P31644 1/20 0.53
GABRA3 P34903 1/20 0.53
GABRA2 P47869 1/20 0.53
GABRB2 P47870 1/20 0.53
GABRA4 P48169 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30484136 0.93 RECQL (0.67) RECQLMAPTPOLBSMN1; SMN2GFER
SCHEMBL31000389 0.93 RECQL (0.67) RECQLMAPTPOLBSMN1; SMN2GFER
SCHEMBL145366 0.93 RECQL (0.67) RECQLMAPTPOLBSMN1; SMN2GFER
Hydrochloric Acid SCHEMBL27581315 0.92 RECQL (0.65) RECQLMAPTPOLBSMN1; SMN2GFER
Hydrazine SCHEMBL11821861 0.92 RECQL (0.65) RECQLMAPTPOLBSMN1; SMN2GFER
Acetamide SCHEMBL28069463 0.87 ALDH1A1 (0.56) RECQLMAPTSMN1; SMN2S100BGABRP
SCHEMBL6351799 0.84 RECQL (0.64) RECQLMAPTPOLBSMN1; SMN2GFER
SCHEMBL28751447 0.84 RECQL (0.56) RECQLMAPTPOLBSMN1; SMN2GFER
SCHEMBL9853497 0.82 SMN1; SMN2 (0.46) RECQLMAPTPOLBSMN1; SMN2GFER
SCHEMBL9853525 0.82 SMN1; SMN2 (0.46) RECQLMAPTPOLBSMN1; SMN2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630909-B2 Process for the preparation of nepafenac MYLAN LABORATORIES LTD (IN) 2017-04-25 US disclosed
US-20160214927-A1 Process for the preparation of nepafenac MYLAN LABORATORIES LTD, (IN) 2016-07-28 US disclosed
EP-3013790-A1 PROCESS FOR THE PREPARATION OF NEPAFENAC Mylan Laboratories Ltd. (IN) 2016-05-04 EP disclosed
WO-2014207769-A1 PROCESS FOR THE PREPARATION OF NEPAFENAC MYLAN LABORATORIES LTD (IN) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214927-A1 Process for the preparation of nepafenac SCN2B, SCN3A, SCN2A RECQL 3728/4885MAPT 1784/4885POLB 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.